HomeInsightsStock Comparison

Cohance Lifesciences Ltd vs Kopran Ltd Stock Comparison

Cohance Lifesciences Ltd vs Kopran Ltd Stock Comparison

Last Updated on: Jul 16, 2025

Key Highlights

  • The Latest Trading Price of Cohance Lifesciences Ltd is ₹ 1064 as of 16 Jul 14:55.
  • The P/E Ratio of Cohance Lifesciences Ltd changed from 8.1 on March 2020 to 57.3 on March 2024 . This represents a CAGR of 47.89% over 5 yearsThe P/E Ratio of Kopran Ltd changed from 5.2 on March 2020 to 24.5 on March 2024 . This represents a CAGR of 36.34% over 5 years.
  • The Market Cap of Cohance Lifesciences Ltd changed from ₹ 2564 crore on March 2020 to ₹ 17223 crore on March 2024 . This represents a CAGR of 46.37% over 5 yearsThe Market Cap of Kopran Ltd changed from ₹ 109.65 crore on March 2020 to ₹ 1245 crore on March 2024 . This represents a CAGR of 62.59% over 5 years.
  • The revenue of Cohance Lifesciences Ltd for the Mar '25 is ₹ 412.59 crore as compare to the Dec '24 revenue of ₹ 322.86 crore. This represent the growth of 27.79% The revenue of Kopran Ltd for the Mar '25 is ₹ 175.62 crore as compare to the Dec '24 revenue of ₹ 166.41 crore. This represent the growth of 5.53%.
  • The ebitda of Cohance Lifesciences Ltd for the Mar '25 is ₹ 84.13 crore as compare to the Dec '24 ebitda of ₹ 133.41 crore. This represent the decline of -36.94% The ebitda of Kopran Ltd for the Mar '25 is ₹ 20.35 crore as compare to the Dec '24 ebitda of ₹ 20.01 crore. This represent the growth of 1.7%.
  • The net profit of Cohance Lifesciences Ltd changed from ₹ 120.59 crore to ₹ 38.73 crore over 8 quarters. This represents a CAGR of -43.33% The net profit of Kopran Ltd changed from ₹ 2.77 crore to ₹ 9.68 crore over 8 quarters. This represents a CAGR of 86.94% .
  • The Dividend Payout of Cohance Lifesciences Ltd changed from 23.57 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Kopran Ltd changed from 55.28 % on March 2021 to 41.75 % on March 2024 . This represents a CAGR of -6.78% over 4 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cohance Lifesciences Ltd

  • Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
  • The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
  • The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

About Kopran Ltd

  • Kopran Ltd., incorporated on April 26, 1958, was promoted by the Somani group and is controlled by Parijat Enterprises.
  • The company came out with a public issue at a premium, in Nov.'92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility. Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment.
  • It manufactures semi-synthetic penicillin and is among the world's highest producers in amoxycillin.
  • Kopran also makes penicillin-G acylase, an enzyme made through fermentation.
  • It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US. Kopran's bulk drug plant has been approved by the US FDA and the UK regulatory authorities.

Cohance Lifesciences Ltd News Hub

News

Cohance Lifesciences to announce Quarterly Result

Cohance Lifesciences will hold a meeting of the Board of Directors of the Company on 13 Au...

Read more

28 Jun 2025 09:56

News

Cohance Lifesciences to hold AGM

Cohance Lifesciences announced that the 7th Annual General Meeting(AGM) of the company wil...

Read more

27 Jun 2025 15:41

News

Cohance Lifesciences' API Unit-IV clears USFDA inspection

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the Unite...

Read more

26 May 2025 08:46

News

Suven Pharmaceuticals allots 12.80 cr equity shares

Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value...

Read more

09 May 2025 09:58

News

Suven Pharmaceuticals renamed as Cohance Lifesciences

Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of Indi...

Read more

08 May 2025 09:39

News

Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation

Suven Pharmaceuticals announced that it has received final approval from the Department of...

Read more

26 Apr 2025 12:56

Kopran Ltd News Hub

News

Board of Kopran recommends final dividend

Kopran announced that the Board of Directors of the Company at its meeting held on 15 May ...

Read more

15 May 2025 16:01

News

Kopran to hold board meeting

Kopran will hold a meeting of the Board of Directors of the Company on 15 May 2025. Powere...

Read more

07 May 2025 14:37

News

Kopran jumps as USFDA inspection at subsidiary's plant concludes smoothly

The United States Food and Drug Administration (USFDA) recently carried out a surveillance...

Read more

28 Apr 2025 15:03

News

Kopran to declare Quarterly Results

Kopran will hold a meeting of the Board of Directors of the Company on 11 February 2025. P...

Read more

05 Feb 2025 12:53

News

Kopran allots 36,200 equity shares under ESOP

Kopran has allotted 36,200 equity shares under ESOP on 21 January 2025. With this allotmen...

Read more

21 Jan 2025 18:36

News

Kopran to discuss results

Kopran will hold a meeting of the Board of Directors of the Company on 13 November 2024 Po...

Read more

06 Nov 2024 14:37

SWOT Analysis Of Cohance Lifesciences Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Kopran Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Cohance Lifesciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Kopran Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cohance Lifesciences Ltd and Kopran Ltd

Which company has a larger market capitalization, Cohance Lifesciences Ltd or Kopran Ltd?

Market cap of Cohance Lifesciences Ltd is 40,376 Cr while Market cap of Kopran Ltd is 866 Cr

What are the key factors driving the stock performance of Cohance Lifesciences Ltd and Kopran Ltd?

The stock performance of Cohance Lifesciences Ltd and Kopran Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cohance Lifesciences Ltd and Kopran Ltd?

As of July 16, 2025, the Cohance Lifesciences Ltd stock price is INR ₹1055.4. On the other hand, Kopran Ltd stock price is INR ₹179.4.

How do dividend payouts of Cohance Lifesciences Ltd and Kopran Ltd compare?

To compare the dividend payouts of Cohance Lifesciences Ltd and Kopran Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions